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Genetic Activation, Inactivation, and Deletion Reveal a
Limited And Nuanced Role for Somatostatin-Containing
Basal Forebrain Neurons in Behavioral State Control
Christelle Anaclet,1,2 XRoberto De Luca,1 XAnne Venner,1 XOlga Malyshevskaya,3 XMichael Lazarus,3
XElda Arrigoni,1* and XPatrick M. Fuller1*
1Department of Neurology, Beth Israel Deaconess Medical Center, Division of Sleep Medicine, Harvard Medical School, Boston, Massachusetts 02115,
2Department of Neurobiology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, and 3International Institute for Integrative
Sleep Medicine (WPI-IIIS), University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
Recent studies have identified an especially important role for basal forebrain GABAergic (BFVGAT) neurons in the regulation of behav-
ioral waking and fast cortical rhythms associated with cognition. However, BFVGAT neurons comprise several neurochemically and
anatomically distinct subpopulations, including parvalbumin-containing BFVGAT neurons and somatostatin-containing BFVGAT neu-
rons (BFSOM neurons), and it was recently reported that optogenetic activation of BFSOM neurons increases the probability of a wakeful-
ness to non-rapid-eye movement (NREM) sleep transition when stimulated during the rest period of the animal. This finding was
unexpected given that most BFSOM neurons are not NREM sleep active and that central administration of the synthetic somatostatin
analog, octreotide, suppresses NREM sleep or increases REM sleep. Here we used a combination of genetically driven chemogenetic and
optogenetic activation, chemogenetic inhibition, and ablation approaches to further explore the in vivo role of BFSOM neurons in arousal
control. Our findings indicate that acute activationor inhibitionofBFSOMneurons is neitherwakefulnessnorNREMsleeppromoting and
is without significant effect on the EEG, and that chronic loss of these neurons is without effect on total 24 h sleep amounts, although a
small but significant increase in waking was observed in the lesioned mice during the early active period. Our in vitro cell recordings
further reveal electrophysiological heterogeneity in BFSOM neurons, specifically suggesting at least two distinct subpopulations. To-
gether, our data support the more nuanced view that BFSOM neurons are electrically heterogeneous and are not NREM sleep or wake
promoting per se, but may exert, in particular during the early active period, a modest inhibitory influence on arousal circuitry.
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Introduction
An important, if indispensable, role for the cellular basal fore-
brain (BF) in behavioral and electrocortical arousal has been pre-
viously established, in particular for BF GABAergic (BFVGAT)
neurons (Buzsaki et al., 1988; Fuller et al., 2011; Anaclet et al.,
2015; Kim et al., 2015; Xu et al., 2015). For example, acute che-
Received Oct. 13, 2017; revised March 26, 2018; accepted April 24, 2018.
Author contributions: C.A., R.D.L., A.V., E.A., and P.M.F. designed research; C.A., R.D.L., and A.V. performed
research; O.M., M.L., E.A., and P.M.F. contributed unpublished reagents/analytic tools; C.A., R.D.L., A.V., E.A., and
P.M.F. analyzed data; C.A., R.D.L., A.V., E.A., and P.M.F. wrote the paper.
This work was supported by National Institutes of Health Grants K99-MH-103399 and R00-MH-103399 (C.A.);
NS-073613,NS-092652, andNS-103161 (P.M.F.); andNS-091126 (E.A.).We thankTilarMartin, RebeccaBroadhurst,
Lauren Sohn, Minh Ha, and Quan Hue Ha for technical assistance.
*E.A. and P.M.F. are co-senior authors.
Correspondence should be addressed to either of the following: Elda Arrigoni, Department of Neurology,
Beth Israel Deaconess Medical Center, 330 Brookline Avenue, E/CLS 705, Boston, MA 02215, E-mail:
earrigon@bidmc.harvard.edu; or Patrick M. Fuller, Department of Neurology, Beth Israel Deaconess Medical
Center, 330 Brookline Avenue, E/CLS 707, Boston, MA 02215, E-mail: pfuller@bidmc.harvard.edu.
DOI:10.1523/JNEUROSCI.2955-17.2018
Copyright © 2018 the authors 0270-6474/18/385168-14$15.00/0
Significance Statement
The cellular basal forebrain (BF) is a highly complex area of the brain that is implicated in a wide range of higher-level neurobio-
logical processes, including regulating andmaintaining normal levels of electrocortical and behavioral arousal. The respective in
vivo roles of BF cell populations and their neurotransmitter systems in the regulation of electrocortical and behavioral arousal
remains incompletely understood. Here we seek to define the neurobiological contribution of GABAergic somatostatin-
containingBFneurons to arousal control.Understanding the respective contributionofBFcell populations to arousal controlmay
provide critical insight into the pathogenesis of a host of neuropsychiatric and neurodegenerative disorders, including Alzhei-
mer’s disease, Parkinson’s disease, schizophrenia, and the cognitive impairments of normal aging.
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mogenetic andoptogenetic activationofBFVGATneurons, including
those containing the calcium binding protein parvalbumin
(Parv), rapidly induces behavioral waking and fast cortical
rhythms associated with cognition (Anaclet et al., 2015; Kim et
al., 2015; Xu et al., 2015). By contrast, acute chemogenetic inhi-
bition of BFVGAT neurons during the early subjective night (active
period) increases non-rapid-eyemovement (NREM) sleep and cor-
tical slow-wave activity (Anaclet et al., 2015).Hence, BFVGAT neu-
rons appear to be both sufficient and necessary for normal
behavioral and EEG wakefulness (W). However, the BF contains
several neurochemically and anatomically distinct subpopula-
tions of BFVGAT neurons beyond Parv, including a population
of BFVGAT neurons that contain the neuropeptide somatostatin
(BFSOM; Yang et al., 2017). Interestingly, BFSOM and BFParv neu-
rons derive from the same embryonic progenitors, raising the
possibility that BFSOM neurons may contribute to the wake-
promoting and EEG-activating responses seen following the ac-
tivation of BFParv neurons (Hu et al., 2013). This possibility,
however, seems unlikely given findings from a recent study that
showed that optogenetic stimulation of BFSOM neurons in-
creased the probability of a wakefulness to NREM sleep transi-
tion, and not a NREM to wakefulness transition, during the
normal rest period of the animal (Xu et al., 2015). Yet it remains
a challenge to reconcile a NREM sleep-promoting role for BFSOM
neurons given that themajority of BFSOMneurons are notNREM
sleep active (Xu et al., 2015) and that the administration of oc-
treotide, a synthetic SOM analog, was found to either suppress
NREM sleep or increase rapid-eyemovement (REM) sleep in rats
(Hajdu et al., 2003; Ziegenbein et al., 2004) and impairs deep
sleep in humans (Ziegenbein et al., 2004). Moreover, a role for
BFSOMneurons in feeding and anxiety, both ofwhich arewaking-
related behaviors, has been described recently (Zhu et al., 2017).
Perhaps most importantly, key evidence for a sleep- or wake-
promoting role for BFSOM neurons, taking the form of a loss of
function (acute inhibition or chronic loss) experiments, is lacking.
Hence, and building upon on prior experimental work that
established a key regulatory role for BFVGAT neurons in neurobe-
havioral and electrocortical arousal (Anaclet et al., 2015), we used
a combination of genetically driven chemogenetic and optogenetic
activation, chemogenetic inhibition, and ablation approaches to
more definitively assess the in vivo role of BFSOM neurons, as a ge-
netically defined subgroupofBFVGATneurons (Yang et al., 2017), in
sleep–wake regulation.
Materials andMethods
Animals. Adult male and female SOM-ires-Cre mice (age, 8–12 weeks;
weight, 20–25 g; n  42 in vivo; n  11 in vitro), obtained from The
Jackson Laboratory, were used in this study. The SOM-ires-Cre (or Sst-
IRES-Cre knock-in allele) has an internal ribosome entry site and Cre
recombinase in the 3 UTR of the somatostatin locus (Sst). These mice
have been used and histologically validated in a previous study (Xu et al.,
2015). All mice were bred at our animal facility and underwent genotyp-
ing both before and after experiments, and all procedures were approved
by the Institutional Animal Care and Use Committee of Beth Israel
Deaconess Medical Center.
Surgery. Mice were anesthetized with ketamine/xylazine (100 and 10
mg/kg, i.p., respectively) and then placed in a stereotaxic apparatus. To
selectively express the hM3Dq receptors in GABAergic somatostatin-
expressing (SOM) neurons of the BF (diagonal band, magnocellular
preoptic nucleus, and ventral regions of the substantia innominata and
ventral pallidum), we placed bilateral injections of an adeno-associated
viral (AAV; serotype 10) vector expressing the hM3Dq receptor in a cre-
dependent configuration [hSyn-DIO-hM3Dq-mCherry-AAV (hM3Dq-
AAV)] into the BF [coordinates: anteroposterior (AP)0.02mm; lateral
(L)1.45mm;dorsoventral (DV)4.80mm(asper themouseatlasof
Paxinos and Franklin, 2001)] of homozygous SOM-ires-Cre (BFSOM-hM3Dq,
n 8). To selectively express the hM4Di receptors in SOM neurons of
the magnocellular BF, we placed bilateral injections of an AAV (serotype
10) vector expressing the hM4Di receptor in a cre-dependent configuration
[hSyn-DIO-hM4Di-mCherry-AAV (hM4Di-AAV)] into the BF of
heterozygous SOM-ires-Cre, lox-L10GFP (BFSOM-hM4Di, n 5)mice. To
selectively kill SOM neurons of the magnocellular BF, we placed bilateral
injections of an AAV (serotype 10) vector expressing the diphtheria toxin
subunit A (DTA) in a cre-dependent configuration [hSyn-DIO-DTA-
mCherry-AAV (DTA-AAV)] into the BF of heterozygous SOM-ires-Cre,
lox-L10GFP (BFSOM-DTA, n 11) mice. A vector injection control [hSyn-
DIO-mCherry-AAV (mCherry-AAV)] was placed into the BF of littermate
heterozygous SOM-ires-Cre, lox-L10GFP mice (BFSOM-mCherry, n  5).
Injections of hM3Dq-AAV, hM4Di-AAV, or DTA-AAV (60 nl) into the
BF of these mice were performed using a compressed air delivery system
as described previously (Fuller et al., 2011). The scalp wound was closed
with surgical sutures, and the mouse was kept in a warm environment
until resuming normal activity, as described previously. In a separate
surgery taking place at least 2 weeks after brain injection, mice were
implanted with four EEG screw electrodes (two frontal and two parietal
electrodes; catalog #8403, Pinnacle Technology) and two flexible electro-
myogram (EMG) wire electrodes (catalog #E363/76/SPC, Plastics One)
previously soldered to a six-pin connector (catalog #853-43-006-10-
001000, Heilind Electronics), and the assembly was secured with dental
cement (Anaclet et al., 2014). The frontal electrodes were positioned 1
mm frontal and 1 mm lateral of bregma, whereas the parietal electrodes
were positioned 1mm lateral from bregma andmidway between bregma
and lambda. For the in vivo optogenetic experiments, SOM-ires-Cre
(BFSOM-ChR2, n  11) and VGAT-ires-Cre (BFVgat-ChR2, n  2) mice
were stereotaxically injected with 60 nl of AAV8-FLEX-EF1-channel-
rhodopsin-2 (ChR2)-mCherry [bilateral: (AP)  0.02 mm; lateral
(L)  1.45 mm; dorsoventral (DV)  4.80 mm (as per the mouse
atlas of Paxinos and Franklin, 2001)], and optical fibers [200 m, 0.39
numerical aperture (NA)] were implanted so that the fiber tip targeted a
region 0.2 mm dorsal to the injection site (bilateral: (AP)0.02 mm;
lateral (L)  1.45 mm; dorsoventral (DV)  4.40 mm). Of the 11
BFSOM-ChR2 mice, we excluded 4 mice, based upon histology, that
showed caudal placement of fiber/injection. Our final analysis, therefore,
includes 7 BFSOM-ChR2 mice that had good bilateral placement of the
optical fibers andChR2 expressionwithin the BF. Allmicewere equipped
with a headset for recording EEG/EMG, as previously described for che-
mogenetic experiments. Optical fibers and headset were secured in place
first with a mixture of dental cement and cyanoacrylate glue to affix the
hardware to the skull and second with dental cement alone to build a stable
headcap and provide electrical insulation for the EEG/EMG headset.
Sleep–wake monitoring—chemogenetics. Two weeks after EEG/EMG
implantation, themicewere housed individually in transparent barrels in
an insulated sound-proofed recording chamber maintained at an ambi-
ent temperature of 22 1°C and on a 12 h light/dark cycle [lights on at
7:00 A.M.; or zeitgeber time 0 (ZT0)] with food and water available ad
libitum. Mice were habituated to the recording cable for 5–7 d before
starting a polygraphic recording. Cortical EEG (ipsilateral frontoparietal
leads) and EMG signals were amplified and digitalized with a resolu-
tion of 500 Hz using VitalRecorder software (Kissei). BF SOM-DTA and
BF SOM-mCherry control mice were subjected to 48 h of baseline record-
ing. (BFSOM-hM3Dq and BFSOM-hM4Di mice were recorded for a 24 h
baseline period followed by injections of clozapine-N-oxide (CNO; 0.3
and 0.9 mg/kg in saline, i.p.; Sigma-Aldrich) injections at 10:00 A.M. (or
ZT3; light period, time of high sleeping drive) and 7:00 P.M. (or ZT12;
lights-off, time of high activity). As control injections, mice were injected
with saline at 10:00 A.M. and 7:00 P.M. CNO and saline injections were
performed in a random sequence and separated by a 3–5 d washout
period. The injections were performed using a crossover design. Data
were scored off-line using SleepSign for Animals software (Kissei).
Sleep–wake monitoring—optogenetics. At least 2 weeks following opti-
cal fiber/EEG implant surgeries, mice were habituated to the recording
chamber and recording equipment (electrical cables plus bilateral optical
patch cables; 200 m, 0.39 NA) for 5 d before commencing the experi-
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ment. A 473 nm blue light (LASERGLOW Technologies) was used to
activate ChR2 in BF neurons with an estimated power output at the tip of
the optical fiber of 12–15mW. The stimulation paradigm consisted of 10
ms light pulses, delivered at a frequency of 2.5 or 10 Hz continuously, for
1 min every 10 min for a 3 h window during the light period (between
9:00 A.M. and 3:00 P.M.). Stimulations were controlled using the digital
output of a Micro 1401–3 data acquisition unit and Spike version 2.08
software (Cambridge ElectronicDesign).Mice were given 1 d of recovery
between each stimulation frequency. The electrical signal from the EEG/
EMG headset was amplified by 20,000 using an AM SystemsModel 3500
amplifier and digitized at 500Hz using theMicro 1401–3 unit. Data were
scored off-line using Spike version 2.08 software.
hM3Dq/hM4Di-AAV and clozapine-N-oxide. For the in vivo and in
vitro studies, we used evolved G-protein-coupled muscarinic receptors
(hM3Dq and hM4Di) that are selectively activated by the pharmacolog-
ically inert drug CNO. This system was first developed and described by
the Roth laboratory (Alexander et al., 2009). In our studies, cre-dependent
versions of the hM3Dq andhM4Di receptorswere packaged into anAAV to
facilitate the stereotaxic-based delivery and regionally restricted expression
of hM3Dq and hM4Di. As demonstrated previously by our laboratory
(Anaclet et al., 2014, 2015, 2018; Venner et al., 2016; Pedersen et al., 2017)
and others, both the hM3Dq/hM4Di receptors and ligand are biologi-
cally inert in the absence of ligand.Moreover, at the administered dose of
0.3 mg/kg, CNO injection (1) does not affect sleep–wake quantity or
quality in wild-type control mice and (2) induces a maximum effect
during the 1–3 h postinjection period (Anaclet et al., 2014, 2018).We are
therefore confident that the sleep–wake effects described in our studies
result from specific activation or inhibition of the targeted neuronal
population and not from a nonspecific effect of CNO or its metabolite
clozapine (Gomez et al., 2017).
Sleep scoring and analysis. Using SleepSign for Animal (Kissei) and
with the assistance of spectral analysis using fast Fourier transform
(FFT), polygraphic records were visually scored by 10 s epochs for W,
NREM sleep, and REM sleep. The percentage of time spent inW, NREM
sleep, and REM sleep, as well as the number and the average durations of
the episode were summarized for each group and each condition. The
latency to NREM sleep and REM sleep are defined as the time between
the end of the injection and the onset of the first NREM sleep episode
lasting20 s and the first REM sleep episode lasting10 s.
Recordings were scored again in 5 s epochs to allow for the perfor-
mance of an EEG power spectrum analysis, during the 3 h postinjection,
when the effect of CNO is at itsmaximum (Anaclet et al., 2014, 2015). On
the basis of visual and spectral analysis, epochs containing artifacts oc-
curring during active wakefulness (with large movements) or containing
two vigilance states were visually identified and omitted from the spectral
analysis. Recordings containing wake artifact during 20% of the time
were removed from the spectral analysis. EEG power spectra were com-
puted for consecutive 5 s epochs within the frequency range of 0.5–120
Hz using an FFT routine. The data were collapsed into 0.5 Hz bins. The
data were standardized by either expressing each frequency bin as a per-
centage relative to the total power (e.g., bin power/total power: 0.5/120
Hz) of the same epochs; or expressing each frequency bin as a percentage
relative to the same bin in baseline condition from the same mouse and
from the same time of the day (same zeitgeber time). To analyze the EEG
frequency bands, relative power binswere summed in delta (, 0.5–5Hz),
theta (, 5–9 Hz), sigma (, 9–15 Hz), beta (, 15–30 Hz), low gamma
(l, 30–60 Hz), and high gamma (h, 60–120 Hz).
The individuals performing the saline/CNO injections and sleep–wake
analysis were blinded to the initial immunohistochemical assessment of
the injection sites.
Statistical analysis. Statistical analysis was performed using Prism ver-
sion 6 (GraphPad Software). Following confirmation that the data met
the assumptions of the ANOVA model, a two-way ANOVA followed by
a post hoc Bonferroni test were used to compare the effects of the geno-
type or the drug injection on sleep–wake parameters. One-way ANOVA
was used to analyze the latency toNREM sleep or REM sleep. Sample size
and power calculations were performed post hoc at http://www.biomath.
info, using means and SDs derived from our analysis. The present study
was sufficiently powered to detect effect sizes.
Immunohistochemistry. Animals received CNO (0.3 mg/kg, i.p., at
10:00 A.M.) and were killed 2 h later by deep anesthesia with 200 mg/kg
chloral hydrate, followed by transcardial perfusion with 20 ml of saline,
followedby 100ml of neutral phosphate-buffered formalin (4%;Thermo
Fisher Scientific). Brains were removed, incubated in 20% sucrose at 4°C
until they sank, and then sectioned at 40 m on a freezing microtome in
three series. For all c-Fos andDsRed immunohistochemical staining that
involved visualization using a diaminobenzidine reaction, the sections
were incubated overnight with primary antiserum (c-Fos, 1:20,000;
DsRed, 1:10,000) and then incubated in the respective secondary anti-
bodies for 2 h, followed by incubation in ABC reagents (1:1000; Vector
Laboratories) for 90 min, then washed again and incubated in a 0.06%
solution of 3,3-diaminobenzidine tetrahydrochloride (Sigma-Aldrich)
or 0.06% solution of 3,3-diaminobenzidine tetrahydrochloride and
0.05% CoCl2 and 0.01% NiSO4 (NH4) in PBS plus 0.02% H2O2 for 5
min. Finally, the sections were mounted on slides, dehydrated, cleared,
and coverslipped. Sections for immunofluorescence staining were incu-
bated in fluorescent-labeled secondary antibody (Ab) for 2 h and cover-
slipped with DAPI-infused fluorescence mountingmedia.
Antibody characterization. The rabbit polyclonal Fos antibody was
raised against a synthetic peptide including residues 4–17 from human
c-Fos (rabbit polyclonal Ab; catalog #Ab5, Oncogene Sciences; note that
this Ab is no longer commercially available). This antibody stained a
single band of 55 kDa on Western blots from rat brain (technical infor-
mation from manufacturer). c-Fos staining with the Ab5 antiserum is
found in many CNS structures only when neurons within these struc-
tures have recently been physiologically stimulated.
The rabbit polyclonal antibody against mCherry was raised against
DsRed (catalog #632496, Clontech), and the specificity of immunostain-
ing for DsRed was indicated by the lack of detectable immunostaining in
uninjected mice.
For all secondary antibody immunohistochemical controls, the pri-
mary antibodies were omitted and the tissue showed no immunoreactiv-
ity above background. Secondary antibodies included the following:
donkey anti-rabbit Alexa Fluor 546 (1:500; Invitrogen) and donkey anti-
rabbit biotinylated (1:500; Invitrogen).
Packaging of DIO-hM3Dq and DIO-hM4D AAVs. We used the
pAAV-hSyn-DIO-hM3D-mCherry and pAAV-hSyn-DIO-hM4D-mCherry
plasmids (gift from B. Roth, UNC Chapel Hill, North Carolina) to pro-
vide the Cre-dependent hM3D transgene for packaging into AAV2/10.
Packaging was performed using a standard triple-transfection protocol
to generate helper virus-free pseudotyped AAV2/10 virus (Anaclet et al.,
2015). An AAV 2/10 rep/cap plasmid provided AAV2 replicase and
AAV10 capsid functions (Gao et al., 2002; De et al., 2006), while adeno-
viral helper functions were supplied by the pHelper plasmid (Strat-
agene). Briefly, AAV-293 cells were transfected via calcium phosphate
precipitation with 1.33 pmol pHelper, and 1.15 pmol each of AAV2/10
and an AAV vector plasmid (double floxed). The cells were harvested
72 h later, and the pellets were resuspended in DMEM, freeze-thawed
three times and centrifuged to produce a clarified viral lysate. The vector
stocks were titered by real-time PCR using an Eppendorf Realplex ma-
chine as previously described (Gao et al., 2002). The titer of the prepara-
tions ranged from 1 	 1012 to 1 	 1013 vector genomes copies/ml.
Before initiating the in vivo experiments, an absolute requirement for
Cre-enabled expression of hM3Dq and hM4Di was confirmed in vitro
using 293 cre cells.
Packaging of DTA-AAV. Drs. P. Fuller (BIDMC), O. Malyshevskaya
and M. Lazarus (Tsukuba University) developed a new and enhanced
version of our previously published DTA (Kaur et al., 2013), which was
used in the current study. For the pAAV-FLEX-DTA plasmid, a FLEX-
DTA cassette that consists of (5 to 3) a lox2272 site, anmCherry coding
sequence, a human growth hormone polyadenylation signal sequence, a
loxP site, an inverted DTA sequence, and inverted lox2272 and loxP sites
was synthesized by Eurofins Genomics K.K. and inserted between the
ClaI and BamH I restriction sites in a pAAV-MCS vector (Stratagene). In
this design, mCherry was expressed in all non-cre-recombinase cells
within the injection field, thereby allowing us to ascertain (1) the ana-
tomic extent of the injection and (2) “survival” of the non-cre-
recombinase cells intermingled with the cre-recombinase cells targeted
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Figure 1. Evidence that BF SOM hM3Dq and hM4Di neurons are excited and inhibited, respectively, by CNO in in vitro brain slices, experimental design, and BF SOM cell distribution. Injections
of DIO-hM3Dq-mCherry-AAV, DIO-hM4Di-mCherry-AAV, or DIO-mCherry-AAV were placed into the BF of SOM-ires-Cre mice, resulting respectively in the expression of hM3Dq-mCherry, hM4Di-
mCherry, or mCherry in BF SOM neurons. Whole-cell recordings in brain slices were conducted 5–6 weeks after the AAV injections. A, Microphotographs showing the distribution of the recorded
neurons labeledwith biocytin. After incubation in fluorescent streptavidin, 13 of 29 recorded neurons were recovered, mapped, and represented (red dots, indicating BF SOM neurons with LTS, n
7; green dots representing non-LTS BF SOM neurons, n 6) over the images of two recorded slices (rostral level, top image; caudal level, lower image). Scale bar, 1mm. Ac, Anterior commissure; 3V,
third ventricle; Ox, optical chiasm;VP, ventral pallidum; SI, substantia innominata;MCPO,magnocellular preoptic nucleus; HDB, horizontal diagonal band).B,C, Firingproperties of twodistinct types
of BF SOM neurons: one group of BF SOM neurons responds to depolarizing (left) and hyperpolarizing (right) current pulse protocols with LTS (B), and the other group has no LTS (C). The vastmajority
of BF SOM neurons have an Ih. D, E, hM3Dq-mCherry-expressing BF
SOM neurons (top) visualized under IR-DIC during whole-cell recordings (bottom; (Figure legend continues.)
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by DTA. See Figure 5B for construct (CMV--globin-DIO-mCherry-
DTA-hGH pA) details.
AAV of serotype rh10 for AAV-FLEX-DTA were generated by tripar-
tite transfection (AAV-rep2/caprh10 expression plasmid, adenovirus
helper plasmid, and pAAV plasmid) into 293A cells. After 3 d, the 293A
cells were resuspended in artificial CSF (ACSF), freeze thawed four times,
and treated with Benzonase nuclease (Millipore) to degrade all forms of
nonviral DNA and RNA. Subsequently, the cell debris were removed by
centrifugation, and the virus titer in the supernatant was determined
with an AAVpro Titration Kit for Real Time PCR (Takara).
Whole-cell in vitro experiments. Bilateral injections (120 nl) of DIO-
hM3Dq-mCherry-AAV,DIO-hM4Di-mCherry-AAVorDIO-mCherry-
AAV were placed into the BF of SOM-Cre mice (n 11 mice). Five to 6
weeks after AAV injections, the mice were used for in vitro electrophysi-
ological recordings. Mice were deeply anesthetized with isoflurane (in-
halation; 5% in oxygen) and transcardially perfusedwith ice-cold cutting
ACSF [N-methyl-D-glucamine (NMDG)-based solution] containing the
following (inmM): 100 NMDG, 2.5 KCl, 1.24 NaH2PO4, 30 NaHCO3, 25
glucose, 20 HEPES, 2 thiourea, 5 Na-L-ascorbate, 3 Na-pyruvate, 0.5
CaCl2, and 10MgSO4, pH7.3, withHClwhen carbogenatedwith 95%O2
and 5% CO2 (310–320 mOsm). Coronal slices (250 m thickness) were
cut in ice-cold cutting ACSF using a vibratingmicrotome (VT1200S, Leica).
Slices were first kept in cutting ACSF at 37°C for 5 min and then
transferred in normal ACSF at 37°C. Slices were then allowed to
gradually return to room temperature for an hour. Normal ACSF
contained the following (in mM): 120 NaCl, 2.5 KCl, 1.3 MgCl2, 10
glucose, 26 NaHCO3, 1.24 NaH2PO4, 4 CaCl2, 2 thiourea, 1 Na-L-
ascorbate, and 3 Na-pyruvate, pH 7.4 when carbogenated with 95% O2
and 5% CO2 (310–320 mOsm).
Slices containing the BF were recorded in oxygenated (95% O2, 5%
CO2) normal ACSF at room temperature. Recordings were conducted in
whole-cell configuration and in current-clamp mode using a K-gluconate-
based pipette solution containing the following (in mM): 120 K-Gluconate,
10 KCl, 3 MgCl2, 10 HEPES, 2.5 K-ATP, and 0.5 Na-GTP, pH 7.2 ad-
justed with KOH (280mOsm). Biocytin (0.5%) was added to the pipette
solution to fill and mark the recorded neurons. Recordings were con-
ducted using a MultiClamp 700B Amplifier, a Digidata 1440A Digitizer
Interface, and pClamp version 10 software (Molecular Devices). Neu-
rons showing changes in input resistance10%over timewere excluded
from the analysis. BF mCherry-labeled somatostatin neurons were
visualized through a combination of fluorescence and infrared (IR)-
differential interference contrast (DIC) video microscopy using a fixed-
stage upright microscope (BX51WI, Olympus America) equipped with a
Nomarski water-immersion lens (40	/0.8 NAW, Olympus) and IR-
sensitive CCD camera (ORCA-ER, Hamamatsu). Images were acquired
in real time using a Matlab (MathWorks) script.
Recording data were analyzed using Clampfit version 10 (Molecular
Devices). Firing frequencies and membrane potentials were analyzed
using MiniAnalysis (Synaptosoft) and Matlab (MathWorks). Data were
represented as the mean SEM; n indicates number of cells per group.
Groupmeans were compared using paired t tests. The effects of CNO on
firing frequency and membrane potential were analyzed by comparing 5
min of recordings just before CNO applications (control period) and
during the last 5 min of a 10 min CNO application. Figures were gener-
ated using Photoshop (Adobe), Igor Pro version 6 (WaveMetrics) and
Prism 7 (GraphPad).
Immediately following the in vitro recordings, recorded slices were
fixed in 10% buffered formalin (overnight), then washed and incubated
in streptavidin-conjugated Alexa Fluor 405 (1:500, 24 h; Invitrogen).
Images were acquired using a confocal microscope (LSM 5 Pascal, Zeiss)
and a slide scanner (VS120, Olympus).
Results
In vitro BFSOM activation and inhibition
Whole-cell current-clamp recordings in the BF revealed two pop-
ulations of somatostatin-expressing (BFSOM) neurons with dis-
tinct firing properties (Fig. 1A–C). One population had large
low-threshold spikes (LTSs) that supported burst firing when
neurons were depolarized from hyperpolarized potentials (17 of
29 recorded neurons; Fig. 1B), while the second population
showed tonic firing and no LTSs (12 of 29 recorded neurons; Fig.
1C). The hyperpolarization-activated cation current (Ih) was
present in the majority of BFSOM neurons (25 of 29 neurons).
Both subtypes of BFSOM neurons were capable of expressing
hM3Dq (BFSOM-hM3Dq-mCherry) or hM4Di (BFSOM-hM4Di-mCherry)
receptors following injections of DIO-hM3Dq-mCherry-AAV
and DIO-hM4Di-mCherry-AAV in SOM-ires-Cre mice and re-
sponded to bath application of CNO (0.5–1 M). We tested the
response to CNO in 18 BFSOMneurons. CNO increased the firing
frequency of BFSOM-hM3Dq-mCherry neurons (control, 0.47 0.25
Hz; CNO, 1.81  0.66 Hz; n  6; p  0.0284, paired t test; Fig.
1D–G), and this effect was accompanied by a membrane depo-
larization (control, 44.31  2.02 mV; CNO, 39.26  1.10
mV; n  6; p  0.0018, paired t test). Both firing frequency
and membrane potential returned to control levels after 15 min
of CNO washout. CNO decreased the firing frequency of
BFSOM-hM4Di-mCherry neurons (control: 0.31  0.12 Hz; CNO:
0.04 0.02 Hz; n 6; p 0.0199, paired t test; Fig. 1H–K) and
hyperpolarized their membrane potential (control, 45.52 
1.00 mV; CNO,49.61 0.90 mV; n 6; p 0.0001, paired t
test). Both effects were reversed after 15 min washout. CNO had
no effect on BFSOM-mCherry neurons that lacked hM3Dq or
hM4Di receptors and only expressed mCherry following injec-
tions of DIO-mCherry-AAV (control injections; Fig. 1L–O). No
changes of firing frequency (control, 0.19  0.08 Hz; CNO,
0.21 0.10 Hz; n 6; p 0.1873, paired t test) or in membrane
potential (control,40.94 1.97mV;CNO,40.90 2.14mV;
n 6; p 0.4645, paired t test) in response to CNO (1 M) were
observed in BFSOM-mCherry neurons, confirming that CNO-
mediated activation or inhibition of BFSOM neurons occurs only in
neurons expressing hM3Dq and hM4Di receptors.
In vivo BFSOM chemogenetic activation
Following bilateral injections of hM3Dq-AAV, transduced so-
mata (hM3Dq) were consistently observed in the horizontal
limb of the diagonal band, magnocellular preoptic area, and sub-
stantia innominata and spanned, rostrally caudally, from bregma
0.26 to 0.82 (Figs. 1P,Q, 2A). As we have shown previously
(Anaclet et al., 2014), the administration of CNO (the hM3Dq
ligand; 0.3 mg/kg, i.p.) consistently produced robust c-Fos expres-
sion in hM3Dq neurons (Fig. 2B). To test the putative sleep-
promoting action of BFSOM neurons in vivo, BFSOM-hM3Dq mice
(n 8) received injection of CNO (0.3 or 0.9 mg/kg) at the begin-
ning of the dark period, a time of high waking drive in mouse
4
(Figure legend continued.) scalebars, 20m)showedan increase in firing frequency in response
to the bath application of CNO (1M; dotted lines, 0 mV). F, Averaged response on the firing
frequency of hM3Dq-expressing BF SOM neurons (n 6) to 10 min application of CNO (0.5–1
M). G, Confocal images of a recorded BF SOM neuron (filled with biocytin and labeled in blue;
top) that expresses hM3Dq-mCherry (native fluorescence; bottom; scale bars, 20 m).
H, I, hM4Di-mCherry expressing BF SOM neurons (top) visualized under IR-DIC (bottom; scale
bars, 20 m) reduced their firing frequency in response to CNO (1 M; dotted lines, 0 mV).
J, Averaged response of hM4Di-expressing BF SOM neurons to CNO (0.5–1M; n 6). K, Con-
focal image of a recorded BF SOM neuron (top, biocytin labeled in blue; bottom, mCherry native
fluorescence; scale bars, 20m). L–N, Non-hM3Dq or non-hM4Di expressing BF SOM neurons,
recorded from SOM-Cremice injectedwith DIO-mCherry-AAV, control injections (top:mCherry;
bottom: IR-DIC; scale bars: 20m)did not respond to CNO (1M; dotted lines, 0mV;n 6).O,
Confocal images of a recorded BF SOM neuron (top, biocytin labeled in blue; bottom, mCherry
native fluorescence; scale bars, 20m).P, Experimental design for the chemogenetic-based in
vivo experiments.Q, Coronal section from a Som-ires-cre, lox-GFPL10 reporter cross (box shows
targeted region of BF; scale bar, 1 mm).
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Figure 2. Absence of sleep–wake changes following chemogenetic activation of BF SOM neurons. A, B, Photomicrographs showing transfection of BF SOM neurons (A) and their robust activation
(B) following CNO in vivo (green arrows indicate hM3Dq cells expressing c-Fos).C1–F3, Sleep–wakephenotypes following injection of vehicle and CNO (0.3mg/kg and0.9mg/kg) in BF SOM-hM3Dq
mice.C, Hourly amount (SEM)of the vigilance stages and sleep latencies inBF SOM-hM3Dqmousegroup (n8mice).D, Power spectrumchanges (SEM)over baselineduring the3hpostinjection
period for vehicle injection comparedwith the 3 h postinjection period for CNO (0.3 and 0.9mg/kg) administration and the quantitative changes (SEM) in power for the delta (. 0.5–5 Hz), theta
(, 5–9 Hz), sigma (, 9 –15 Hz), beta (, 15–30 Hz), low-gamma (l, 30–60 Hz), and high-gamma (h, 60–120 Hz) frequency bands (n 8 mice). E, F, Number of episodes (SEM) of
wakefulness (W), NREM sleep, or REM sleep in each bout length (E) and time-weighted frequency histograms (F) showing the proportion (SEM) of wakefulness, (Figure legend continues.)
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(Fig. 2C). CNO dosage had no effect on NREM sleep (one-way
ANOVA, F(1.89,13.22)  0.32, p  0.72) or REM sleep (one-way
ANOVA, F(1.26,8.84) 0.45, p 0.56) latency, suggesting that the
activation of BFSOM neurons does not affect sleep onset. CNO
dosage had no effect on the hourly amount of NREM sleep (two-
way ANOVA, F(2,14)  0.83, p  0.45) or REM sleep (two-way
ANOVA, F(2,14)  1.43, p  0.27) amount, suggesting that the
activation of BFSOM neurons does not affect sleep behavior. Cor-
tical EEG power spectral analysis during the 3 h postinjection
confirmed that the CNO dosage did not affect frequency distri-
bution during the three vigilance stages (Fig. 2D), indicating no
major influence of BFSOM neurons on cortical activity. Power
was, however, reduced during NREM sleep following CNO ad-
ministration (low CNO dose, 88.5  1.8%; high CNO dose,
89.2  2.2% vs 97.0  2.3% of baseline sigma power during
NREM sleep; p  0.0008 and 0.002, respectively, Bonferroni’s
multiple-comparisons test), suggesting a possible decrease in
spindle activity during NREM sleep. Sleep architecture during
the 3 h postinjection bout number and duration was not affected
byCNOdosage (Fig 2E,F), andCNOadministration (0.3mg/kg,
i.p.) during the light period did not affectNREMsleep (F(23,161)
1.36, p 0.14) or REM sleep (F(23,161) 1.10, p 0.35) hourly
distribution, indicating a very modest influence of BFSOM neu-
rons on sleep–wake regulation.Our findings therefore fail to con-
firm a wake- or sleep-promoting role for BFSOM neurons in vivo
and, moreover, are inconsistent with those from a prior optoge-
netic study suggesting that BFSOM neurons are acutely sleep pro-
moting in vivo (Xu et al., 2015).
In vivo BFSOM chemogenetic inhibition
Similar to the activation experiments, acute inhibition of BFSOM
neurons had limited effects on sleep–wake quantity or quality in
BFSOM-hM4Dimice (n 5; Fig. 3). Specifically, the administration
of CNO (0.3 or 0.9mg/kg, i.p.) waswithout effect onNREMsleep
(one-way ANOVA, F(1.32,5.28)  0.27, p  0.69) or REM sleep
(one-way ANOVA, F(1.06,4.23)  0.39, p  0.58) latency (Fig.
3A2–A3), suggesting that inhibition of BFSOM neurons does not
affect sleep onset. CNO dosage was also without effect on the
hourly amount of wakefulness (two-way ANOVA, F(2,8) 3.76,
p  0.07), suggesting that inhibition of BFSOM neurons did not
affect waking behavior (Fig. 3A1). Cortical EEG power spectral
analysis during the 3 h postinjection period confirmed that CNO
dosage did not affect frequency bands during wakefulness (two-
way ANOVA, F(10,30) 1.60, p 0.15; Fig. 3B1), indicating that
BFSOM neurons are not necessary for cortical activation. The higher
dose of CNO (0.9 mg/kg) did, however, decrease sigma, beta, and
low gammapower band comparedwith both control and lowCNO
(0.3mg/kg) injections duringNREM sleep (Fig. 3B2), indicative of
a decrease of spindle and fast activity during NREM sleep. Sleep
architecture during the 3 h postinjection, bout number, and du-
ration, was not affected by CNO dosage (Fig. 3C,D) confirming
nomajor influence of BFSOM neurons on sleep–wake phenotype.
These results suggest that BFSOM neurons are not necessary for
sleep onset and maintenance, although the spectral results sug-
gest that BFSOM neuronsmay facilitate the “dampening down” of
cortical activity during sleep.
In vivo BFSOM optogenetic activation
As chemogenetic activation of BFSOM neurons was ineffective at
inducing changes in wakefulness or sleep, we next sought to deter-
mine whether activation of this population using an optogenetic
strategy could induce a behavioral state transition. BFSOM-ChR2mice
(n 7; Fig. 4A–B2) received blue light pulses delivered through
the optical fiber at frequencies close to the native firing frequency
of these neurons in vivo (based upon the study by Xu et al., 2015;
10 ms pulses delivered at 2.5 Hz for 1 min; Figure 4C1) and at a
previously investigated stimulus frequency (of 10 ms pulses de-
livered at 10 Hz for 1 min; Figure 4C2; Xu et al., 2015) once every
10 min for 3 h during the light period (between 9:00 A.M. and
3:00 P.M.). Consistent with our chemogenetic findings, optoge-
netic activation of BFSOM neurons did not increase the probabil-
ity of a transition to NREM (or REM) sleep at either stimulation
frequency tested. As a positive control for this stimulation, we
similarly bilaterally stimulated BFVGAT-ChR2 neurons (n  2 mice;
Fig. 4D), which induced a robust increase in wakefulness at both
2.5 and 10Hz.We therefore conclude that the activation of SOM-
containing neurons within the BF (confirmed using two comple-
mentary yet distinct approaches) does not acutely drive sleep or
wakefulness in mice.
BFSOM genetically targeted chronic ablation
To test the sleep–wake effect of the chronic loss of BFSOM neu-
rons, we placed bilateral injections of AAV-DTA into the BF of
SOM-ires-cre,lox-L10GFP mice (BFSOM-DTA, n  11) to selec-
tively and chronically ablate BFSOM neurons (Fig. 5A,B). Histo-
logical analysis of the tissue revealed a90% bilateral reduction
in BFSOM cells (GFP) across the anatomic BF (Fig. 5C–F).With
respect to the physiology of thesemice, the chronic loss of BFSOM
neurons (BFSOM-DTA) resulted in cycles of sleep and wakefulness
that were comparable to control mice (BFSOM-mCherry, n  5;
same genotype as BFSOM-DTA mice; bilateral injection of AAV-
mCherry for viral vector injection control) in the baseline condi-
tion, with minor exceptions. The 24 h wakefulness distribution
was not affected by the loss of BFSOMneurons (two-wayANOVA,
F(1,14) 1.16, p 0.69; Figure 5G1), and, similar to controlmice,
BFSOM-DTA mice were more awake during the dark period com-
pared with the light period (light–dark interaction: two-way
ANOVA, F(1,14) 153.3, p
 0.0001; Fig. 5H1). NREM sleep and
REM sleep displayed opposite variations (Fig. 5G2,G3,H2,H3).
However, wakefulness was significantly increased during the first
4 h of the dark period, a time of high waking drive in the mouse
(87.3 2.6% vs 73.1 5.2% of wakefulness in control mice; p
0.015, unpaired t test, t 2.76, df 14; Figure 5H1). The wake-
fulness amount increases during the first 4 h of the dark period
were at the expense of both NREM sleep (Fig. 5H2) and REM
sleep (Fig. 5H3). The increased wakefulness during the early
active period in BFSOM-DTA mice resulted from a significant de-
crease of the short wakefulness epoch (
30 s: 3.3 0.9 vs 7.8
1.5 episodes in control mice; p 
 0.0001, Bonferroni’s adjust-
ment for multiple comparisons; Fig. 6A1) and a significant in-
crease of the percentage of wakefulness from long wakefulness
epochs (40min: 88.0 3.2%vs 45.3 14.7%ofwakefulness in
control mice; p 
 0.0001, Bonferroni’s adjustment for multiple
comparisons; Fig. 6B1). At the same time, the number of medium-
length NREM sleep episodes (1 min
 NREM sleep epoch
 10
min; Fig. 6A2) was significantly decreased in BFSOM-DTA mice.
The REM sleep epoch number was also affected (two-way
4
(Figure legend continued.) NREM sleep, or REM sleep amounts in each bout length to the total
amountofwakefulness,NREMsleep, or REMsleepduring the3hpostinjectionperiod for vehicle
injection compared with the 3 h postinjection period for CNO (0.3 and 0.9 mg/kg) administra-
tion (n 8). Light green star p
 0.05 between CNO 0.3 mg/kg and control injection; dark
green starp
0.05betweenCNO0.9mg/kgandcontrol injection, two-wayANOVA followedby
a post hoc Bonferroni test. Scale bars: A, 400m; A inset, 100m; B, 70m.
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Figure 3. Absence of sleep–wake changes following chemogenetic inhibition of BF SOM neurons. Sleep–wake phenotypes following the injection of vehicle and CNO (0.3 and 0.9 mg/kg) in
BF SOM-hM4Di mice. A, Hourly amount of wakefulness (W; A1), NREM sleep (NREMS; A2) and REM sleep (REMS; A3) and sleep latencies in BF SOM-hM4Di mouse group (n 5mice). B, Power spectrum
changes (SEM) over baseline during the 3 h postinjection period for vehicle injection comparedwith the 3 h postinjection period for CNO (0.3 and 0.9mg/kg) administration and the quantitative
changes (SEM) in power for thedelta (, 0.5–5Hz), theta (, 5–9Hz), sigma (, 9 –15Hz), beta (, 15–30Hz), low-gamma (l, 30–60Hz), andhigh-gamma (h, 60–120Hz) frequencybands
(n 4mice). C1–C3, D1–D3, Number of episodes (SEM) of W, NREMS, or REMS in each bout length (C) and in time-weighted frequency histograms (D) showing the proportion (SEM) of W,
NREMS, or REMS amounts in each bout length to the total amount of wakefulness, NREM sleep, or REM sleep during the 3 h postinjection period for vehicle injection compared with the 3 h
postinjection period for CNO (0.3 and 0.9 mg/kg) administration (n 5). *p
 0.05 between CNO 0.9 mg/kg and control injection, two-way ANOVA followed by a post hoc Bonferroni test.
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ANOVA, F(1,112) 9.25, p 0.0029), and the numbers of REM
sleep episode lasting 1–2.5 min were significantly decreased
(0.9 0.3 vs 2.0 0.5 episodes in control mice; p
 0.05, Bon-
ferroni’s adjustment for multiple comparisons; Fig. 6A3).
Power spectral analysis revealed a similar power distribution
in BFSOM-DTA mice compared with control mice, during the be-
ginning of the dark period, indicating that the increase in wake-
fulness amount was not associated with the EEG power change.
During the light period, delta band power was decreased during
the waking state (26.7  0.8% vs 28.5  1.0% of total power in
control mice; p 
 0.05, Bonferroni’s adjustment for multiple
comparisons). At the same time, REM sleep theta power was
significantly increased (44.5  1.3% vs 42.5  1.6% of total
power in control mice; p 
 0.05, Bonferroni’s adjustment for
multiple comparisons; Fig. 6C–D).
Thus, beyond a decrease in cortical delta power during wake-
fulness and an increase in theta power during REM sleep, cortical
EEG delta power was not significantly changed during NREM
sleep in BFSOM-DTA mice, indicating that these neurons are not
involved in NREM sleep homeostatic control.
Genotype comparisons
As previous studies using this same SOM-ires-Cre mouse line
have not, to our knowledge, evaluated potential sleep–wake phe-
notypic differences between heterozygous and homozygous
SOM-ires-cre mice, we decided to compare baseline sleep–wake
and EEG between homozygous SOM-ires-Cre and heterozygous
SOM-ires-Cre (i.e., SOM-ires-Cre,lox-L10GFP) mice. To enable a
more direct comparison with our chemogenetic and optogenetic
work, we used homozygous and heterozygous SOM-ires-Cre
mice with bilateral injections of AAVs targeting BFSOM neurons
(hM3Dq-AAV and hM4Di-AAV or mCherry-AAV, respectively).
Baseline recordings (i.e., in the absence of CNO) revealed that
homozygous SOM-ires-Cre mice exhibited significantly more
NREM sleep, at the expense of wakefulness (Fig. 7B1), during the
light period than heterozygous SOM-ires-Cremice (62.2 1.6%
vs 54.5  1.2% of the light period; p 
 0.01) and was associated
with an increase inNREMsleep delta power (42.9 0.7%vs 40.7
1.3% of total power; p
 0.05; Fig. 7E2), suggesting elevated sleep
pressure in the homozygous condition. Interestingly, REM sleep
amountwas significantly decreased during the dark period (3.0
0.3% vs 4.5  0.3% of the dark period, p 
 0.05; Fig. 7D1) in
homozygous SOM-ires-Cremice. Given that SOM-ires-Cremice
were obtained as homozygous breeders, the introduction of
another strain (lox-L10GFP) was necessary to generate the
heterozygous condition, and this could account in part or fully
for the noted differences. Regardless, the possibility of a hypo-
morphic allele cannot be definitively ruled out in the homozy-
gous condition andhence interpretative cautionusing thismouse
line in the homozygous state is warranted.
Discussion
Results from our targeted activation (chemogenetic and optoge-
netic) and inhibition (chemogenetic) studies reveal that BFSOM
neurons, presumably comprisingboth electrophysiologically identi-
fied subpopulations (Fig. 1), are neither sufficient nor necessary to
appreciably and acutely alter the levels of behavioral or EEGwake or
sleep. By contrast, our genetically driven deletion studies suggest
that BFSOM neurons may influence the magnitude of waking as
well as total REM sleep time during the early active period. Our
data also suggest, but donot confirm, that the SOM-ires-Cre allele
may be hypomorphic, biasing increased sleep in the homozygous
condition. Together with previous work showing that optoge-
netic activation of BFSOM neurons during the inactive period
(ZT4 to ZT8) increased the probability of a wake–NREM sleep
transition, and that only a minority of BFSOM neurons (22% of
Figure 4. Absence of sleep–wake changes following optogenetic activation of BF SOM neurons. A, Schematic showing experimental setup. B1, B2, Histological verification of ChR2-mCherry-
expressing neurons within the BF (red), together with optical fiber placement (*) in both a BF SOM-ChR2 (B1) and BF VGAT-ChR2 (B2) mouse. Scale bar, 200m. C1, C2, Arousal state probability plots
from BF SOM-ChR2 mice showing wakefulness (blue), NREM sleep (purple), and REM sleep (red) over time as a percentage of the total number of trials over all mice (n 7) before, during, and after
blue light stimulation (light blue box) at either 2.5 Hz (C1) or 10 Hz (C2). D1, D2, Arousal state probability plots from BF VGAT-ChR2 mice showing wakefulness (blue), NREM sleep (purple), and REM
sleep (red) over time as a percentage of the total number of trials over all mice (n 2) before, during, and after blue light stimulation (light blue box) at either 2.5 Hz (D1) or 10 Hz (D2).
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Figure 5. Sleep–wake quantitative changes following selective ablation of BF SOM neurons. A, Schematic showing experimental design.B, Cartoon of construct expressing the cellular toxin DTA
in a cre-dependent configuration (NBmCherry is expressed in transfected cre-negative cells). C, SOM neurons of the BF of the SOM-ires-cre,lox-L10GFPmouse.D, Injection of DTA-AAV into BF of
SOM-ires-cre, lox-L10GFPmouse; red neurons show extent of cellular transfection and label surviving cells. E, A corresponding section from the samemouse shown inD showing a nearly complete
loss of SOM (green) cells followingDTA-driven ablation. F, the dorsally situated lateral septum,which contains a large number of SOM cells,was unaffected by theDTA-AAV targeting theBF (same
mouseasE; scale barC–E, 200m;F, 400m).G, Hourly amount (SEM)ofwakefulness (W;G1), NREMsleep (NREMS;G2) andREMsleep (REMS;G3) inBF SOM-DTA and controlmousegroups (n
11 and5mice, respectively).H, Amount (SEM) of the vigilance stages during the first 4 h of the dark period (19–23 stages), during the light, dark, and 24hperiods in BF SOM-DTA and controlmouse
groups (n 11 and 5mice, respectively). *p
 0.05, **p
 0.01, two-wayANOVA followedby a post hocBonferroni test (hourly amounts and light/dark analysis) or paired t test (19–23 and 24 h).
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those recorded) were NREM active (Xu et al., 2015), we would
propose a more nuanced and time-of-day-dependent role for
BFSOM neurons in behavioral state control. Specifically, our data
suggest that BFSOMneurons are notNREMsleep-, REMsleep-, or
wake-promoting per se, but may exert, in particular during the
early active period, a modest inhibitory influence on arousal cir-
cuitry, including possibly on local wake-promoting cells within
the BF.While it is unclear what the functional significance of this
Figure 6. Sleep–wake qualitative changes following selective ablation of BF SOM neurons. A, B, Number of episodes (SEM) of wakefulness (W; A1, B1), NREM sleep (NREMS, A2, B2), or REM
sleep (REMS,A3,B3) in each bout length (A) and time-weighted frequency histograms (B) showing the proportion (SEM) ofW, NREMS, or REMS amounts in each bout length to the total amount





0.0001, two-wayANOVA followedbyapost hocBonferroni test.C,D, Power spectrum(SEM)over total powerduring thedarkperiod (19–01;C) and the light
period (10–13;D) and thepowerband (SEM) for thedelta (, 0.5–5Hz), theta (, 5–9Hz), sigma (, 9 –15Hz), beta (, 15–30Hz), low-gamma (l, 30–60Hz), andhigh-gamma (h, 60–120
Hz) frequency bands in BF SOM-DTA and controlmouse groups (n 8 and 5mice, respectively). **p
 0.01, ***p
 0.001, ****p
 0.0001, two-way ANOVA followed by a post hoc Bonferroni test.
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“dampening” effect of BFSOM neurons on active period waking
levels might be, one possibility is that they may help fine tune the
level of behavioral arousal, likely via modulation of neighboring
BF cholinergic and GABAergic neurons, in accordance with situa-
tional-specific cognitive demands. To this end, BFSOM neurons di-
rectly inhibit, via the release of GABA, BF wake-promoting cells,
including cholinergic cells (Xu et al., 2015), the activity of which
is strongly linked to many cognitive processes (Gielow and Za-
borszky, 2017). The time of day of this influence on wakefulness
levels observed in our study would also suggest that the operative
population of BFSOM neurons is wake active, and not sleep active.
The cellular BF and wakefulness
Pharmacologic, lesion, stimulation, chemogenetic, and optoge-
netic studies have established a key role for the BF in electrocor-
tical and behavioral arousal. For example, direct stimulation of
the BF has pronounced activating effects on the cortical EEG
(Berridge and Foote, 1996; Cape and Jones, 2000), whereas le-
sions of the BF increase EEGdelta activity, reducewakefulness, or
result in low-amplitude EEG and behavioral unresponsiveness
(Buzsaki et al., 1988; Fuller et al., 2011; Kaur et al., 2013). Recent
studies, including from our laboratory, have attempted to genet-
ically parse the contribution of individual BF cell populations,
including cholinergic, glutamatergic, andGABAergic cell groups,
in these processes (Anaclet et al., 2015; Kim et al., 2015; Xu et al.,
2015; Yang et al., 2017). For example, optogenetic studies of the
cholinergic BF cell group have indicated that these cell groups (1)
promotes both wakefulness and REM sleep or (2) just wakefulness.
In some contrast, two chemogenetic-based studies showed that
acute activation of BF cholinergic neurons led to fragmentation
Figure 7. SOM-IRES-cre: a hypomorphic allele? A, Comparison of hourly amounts (SEM) of baseline wakefulness (W; A1), NREM sleep (NREMS; A2) and REM sleep (REMS; A3) in BF SOMcre/cre
(homozygous for the Cre allele,n11mice) andBF SOMcre/wt (heterozygous for the Cre allele,n10mice)mousegroups.B1,C1,D1, Amount (SEM)of the vigilance stages during the light, dark,
and 24 h baseline periods in BF SOMcre/cre compared with BF SOMcre/wt mouse groups (n 11 and 10mice, respectively). *p
 0.05, **p
 0.01, two-way ANOVA followed by a post hoc Bonferroni
test (hourly amounts and light/dark analysis) or paired t test (24h).B2,C2,D2, Numberof episode (SEM)ofwakefulness (W),NREMsleep (NREMS), orREMsleep (REMS) ineachbout lengthduring
the light and 24 h periods in BF SOMcre/cre compared with BF SOMcre/wt mouse groups (n 11 and 10 mice, respectively). **p
 0.01, ****p
 0.0001, two-way ANOVA followed by a post hoc
Bonferroni test. E1, E2 and E3, Power spectrum (SEM) over total power during the dark period (19–01) and power band (SEM) for the delta (, 0.5–5 Hz), theta (, 5–9 Hz), sigma (, 9 –15
Hz), beta (, 15–30 Hz), low-gamma (l, 30–60 Hz), and high-gamma (h, 60–120 Hz) frequency bands, in BF SOMcre/cre compared with BF SOMcre/wt mouse groups (n 8 and 9 mice,
respectively). *p
 0.05, ****p
 0.0001, two-way ANOVA followed by a post hoc Bonferroni test.
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of the sleep state and suppressed lower-frequency EEG compo-
nents during NREM sleep, but was not wake-promoting per se
(Anaclet et al., 2015; Chen et al., 2016). With respect to the glu-
tamatergic BF cell group, it was recently reported that optoge-
netic stimulation of glutamatergic BF neurons potently drove
wakefulness from NREM sleep (Xu et al., 2015). Once again in
some contrast, chemogenetic activation of this same cell group
had no effect on sleep latency or consolidation and produced no
changes in the EMG or EEG fast frequencies, but did result in a
small decrease in EEG delta power during NREM sleep, indicat-
ing a contribution to cortical desynchronization (Anaclet et al.,
2015). Finally, investigations of the GABAergic BF cell popula-
tion have revealed, consistently, strong high-frequency EEG- and
wake-promoting responses (Anaclet et al., 2015; Kimet al., 2015).
In the first of the optogenetic-based studies, the authors found
that stimulation of parvalbumin-containing GABAergic BF
(BFParv) neurons elicited cortical gamma band oscillations
(GBOs; 40 Hz activity), linking their activation to higher cog-
nitive function (Kim et al., 2015). In a second published optoge-
netic study, the authors found that optogenetic stimulation of
BFParv neurons elicits waking, but not GBO (Xu et al., 2015).
Finally, in a contemporaneous chemogenetic studywe found that
acute activation of GABAergic BF neurons (BFVGAT) neurons
potently drove wakefulness as well as high-gamma (60–120 Hz)
EEG activity (Anaclet et al., 2015). We further showed that acute
inhibition of BFVGAT neurons during the early dark period, a
typical time of maximal wakefulness in the mouse, resulted in a
significant decrease in behavioral wakefulness, establishing the
necessity of BFVGAT neurons for wakefulness maintenance (Ana-
clet et al., 2015). These rather monolithic waking/EEG activating
responses seen following the activation of BFVGAT neurons belie
the functional and anatomic complexity of theGABAergic BF cell
population, namely the existence of wake-, REM-, and NREM
sleep-active subgroups as well as subgroups that contain different
calcium-binding proteins, such as parvalbumin, calbindin-D28k,
and calretinin, or other markers, including the SOM cell group
investigated in the present study (Yang et al., 2017).
The cellular BF and sleep
Older literaturehas suggested that theBFmaycontain, inaddition to
wake-promoting cell populations, NREM sleep-promoting cir-
cuitry. For example, the BF contains sleep-active cells (Hassani et
al., 2009; Sakai, 2011; Xu et al., 2015), and lesions placed into the
BF of the cat have been reported to increase EEG and behavioral
waking, presumably secondary to the loss of NREM sleep-pro-
moting neurons (McGinty and Sterman, 1968; Szymusiak and
McGinty, 1986). As indicated, a recent optogenetic study re-
vealed a NREM sleep-promoting role for BFSOM neurons (Xu et
al., 2015), suggesting the cellular basis for these wake-promoting
lesions. This finding is, however, difficult to reconcile with the
outcomes from our activation, inhibition, and lesion experi-
ments, which were inconsistent with BFSOM neurons promoting
NREM sleep per se. In fact, the results of our chemogenetic stud-
ies, which used the same vector system and construct as used in
our previous studies to activate BFVGAT (Anaclet et al., 2015),
lateral hypothalamic VGAT (Venner et al., 2016), and supra-
mammillary (Pedersen et al., 2017) or parafacial VGAT (Ana-
clet et al., 2014, 2018) neurons (potently driving wakefulness or
sleep), were acutely underwhelming in this regard. While these
disparate outcomes could link to some unrecognized technical
difference, we feel that a critical reassessment of the articles using
lesions cited in support of the concept that the BF contains
NREM sleep-promoting circuitry may be particular revealing.
Specifically, a review of the lesion maps shown in these articles
suggest that the lesions themselves may have included, in part or
entirety, the ventrolateral preoptic nucleus (VLPO). The VLPO
comprises a major NREM sleep-promoting cell population
within the preoptic forebrain (Sherin et al., 1996; Lu et al., 2000),
and in the cat the VLPO is located laterally adjacent to the BF
(Gaus et al., 2002), and hence, far more lateral from the midline
than in the rodent. At the time that these lesion studies were
published the VLPO had not yet been identified, and as such the
authors of the articles had no a priori reason to assume that the
lesions might have encroached upon this NREM sleep-promo-
ting cell group. Hence, and until shown otherwise, we feel that a
more parsimonious explanation for the increased wakefulness
observed in the BF-lesioned cats is unintended ablation of the
NREM sleep-promoting VLPO, and not disruption/ablation of a
resident NREM sleep-promoting cell group (but see limitations
below).
Limitations
Two technical points must be considered when interpreting our
data. First, in light of the revealed electrophysiological heteroge-
neity in the present study and the variable state-dependent activ-
ity of BFSOM neurons demonstrated by another group (Xu et al.,
2015), it is possible, if not likely, that different subpopulations of
BFSOM neurons subserve different aspects of behavioral state con-
trol. As these putative subsets of BFSOM neurons have not, to our
knowledge, been molecularly defined, the ability to selectively
target BFSOM subpopulations is constrained. Hence, the changes
observed in our measured response variables reflect presumptive
concurrent manipulation of all BFSOM subpopulations, and we
therefore cannot rule out the possibility that, for example, the
manipulation of one subpopulation may antagonize the activity
of the other subpopulations.What is clear fromour experimental
work is that the influence of BFSOM onwakefulness, NREM sleep,
and REM sleep, both in the acute and chronic conditions, are
modest across interrogations and likely dependent on time of
day.
The second consideration is that while the SOM-ires-Cre was
designed as a 3 knockin, our comparison of the heterozygous
versus homozygous condition suggests that itmay be a hypomor-
phic allele. While we could not definitely conclude this on the
basis of our comparison, which included the introduction of a
different strain of mouse, we did find that homozygous SOM-cre
mice exhibited slightly more NREM sleep during the light period
and across the 24 h day than heterozygous SOM-cre mice. The
increase inNREM sleep in the homozygous conditionwas largely
attributable to an increase in the number of 2.5–5 min NREM
sleep episodes. Thus, on the one hand, the increases in total
NREM sleep and 2.5–5min NREM sleep episodes would actually
suggest, in the context of a hypomorphic allele, that SOM-cre
neurons aremodestly wakefulness promoting, and not sleep pro-
moting. On the other hand, our acute activation and inhibition
studies would suggest that the modulation of BFSOM neurons is
not sufficient to appreciably or acutely alter sleep or wakefulness,
whereas our ablation studies suggest that BFSOM neurons may
exert a modest inhibitory influence on waking during the early
active period, an effect that is likely mediated by GABA release
since this effect on waking was not observed in the nonablated,
homozygous mice in which GABA production and release is
unlikely affected. Additionally, our in vitro data, together with
previous optrode data (Xu et al., 2015), suggest considerable het-
erogeneity in the BFSOM population, which would be consistent
with the diversity of modest influences that these neurons appear
to exert on behavioral states.
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Conclusions
Our experimental outcomes suggest a modest and time-of-day-
dependent influence of BFSOM neurons on behavioral state and
are generally inconsistent with the idea that this cell population is
NREM sleep promoting, as was previously proposed. Together
with previous work on the cellular BF, the findings from the
present study not only emphasize strong functional heterogene-
ity across BFVGAT subgroups, but also point to BFParv neurons as
being uniquely wake promoting among the subgroups of BFVGAT
cell populations thus far tested. Also, our lesion findings in par-
ticular suggest the interesting possibility that impairment of
BFSOM neurons may contribute, at least in part, to hyperarousal
phenotypes (e.g., hyperarousal of post-traumatic stress disor-
der). Future studies interrogating other BFVGAT subgroups as
well as defining the circuit basis bywhich they regulate behavioral
states are eagerly awaited.
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